Sartorius AG
Company Profile
Business description
Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.
Contact
Otto-Brenner-Strasse 20
GottingenNI37079
DEUT: +49 5513080
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
13,573
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,365.70 | 24.70 | 0.30% |
CAC 40 | 7,593.87 | 38.00 | 0.50% |
DAX 40 | 22,496.98 | 71.15 | 0.32% |
Dow JONES (US) | 40,939.80 | 270.44 | 0.66% |
FTSE 100 | 8,496.80 | 1.95 | 0.02% |
HKSE | 22,119.41 | 111.30 | 0.51% |
NASDAQ | 17,842.76 | 396.42 | 2.27% |
Nikkei 225 | 36,452.30 | 406.92 | 1.13% |
NZX 50 Index | 12,148.60 | 245.29 | 2.06% |
S&P 500 | 5,640.40 | 71.34 | 1.28% |
S&P/ASX 200 | 8,145.60 | 19.40 | 0.24% |
SSE Composite Index | 3,279.03 | 7.62 | -0.23% |